Guideline

ESMO CPG express update on the management of epithelial ovarian cancer

Read time: 1 mins

Last updated: 1st Feb 2026

Source: European Society for Medical Oncology (ESMO)

Availability: Free full text

Status: Current

ESMO Clinical Practice Guideline express update on the management of epithelial ovarian cancer - European Society for Medical Oncology (ESMO)

This Express Update has been issued in response to the approval of rucaparib and MIRV.

It includes rucaparib as a first-line PARPi maintenance option in EOC.

MIRV is recommended for recurrent, high FRα ovarian cancer after 1-3 prior therapies and platinum-free interval of <6 months.

Updated treatment algorithms support personalised therapy in newly diagnosed and recurrent EOC.

Read full Guideline